$ZTS News

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis: Weakening Fundamentals Overshadow The Discount

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs

Jefferies Downgrades Zoetis to Hold, Lowers Price Target to $83

Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?

Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74

Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug

3 Reasons ZTS is Risky and 1 Stock to Buy Instead

Zoetis (NYSE:ZTS): A Quality Investing Case Study in Animal Health

Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus

Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers

Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure Persists

Zoetis (NYSE:ZTS): A Quality Dividend Stock for Income Investors With Room to Grow

Zoetis Declares Fourth Quarter 2026 Dividend

Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript